Literature DB >> 3550020

The pathogenesis and biochemistry of amyloidosis.

A S Cohen, L H Connors.   

Abstract

The transformation of serum proteins into Congo red-sensitive fibrillar material is requisite for the onset and progression of amyloid disease. All the mechanisms which lead to the disease itself have not been elucidated, but our knowledge has increased significantly. It is apparent that in all types of amyloid fibrils, three common features are displayed by the major protein constituents. These are that the fibril protein has a serum precursor, a high degree of anti-parallel beta-sheet conformation and a distinctive ultrastructure on electron microscopy. In the AL and AA forms of amyloidosis, the putative precursors appear to undergo limited degradation to form the protein component of amyloid fibrils. It has been suggested that there may be certain primary structural characteristics inherent in precursor molecules which make them amyloidogenic, thus predisposing them to amyloid fibril formation. This would include certain subtypes of immunoglobulin light chains, possibly kappa I and lambda VI, in the AL type of amyloidosis and one of the polymorphic SAA species, SAA2, which has been identified as the predominating isotype found in AA amyloid fibrils. In AH amyloidosis, the mechanism of amyloid fibril formation appears to be simply a concentration phenomenon where elevated concentrations of B2-M are not handled normally and amyloid deposition is the result. Amyloidogenesis in the hereditary form of systemic amyloidosis may involve other factors in addition to the presence of a variant precursor prealbumin as indicated by the delayed onset of the disease. It is evident that the elucidation of the mechanism(s) which governs the onset and progression of the amyloidoses will allow future regulation and treatment of these all too often complex disorders.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3550020     DOI: 10.1002/path.1711510102

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  26 in total

Review 1.  Single cell gene expression profiling in Alzheimer's disease.

Authors:  Stephen D Ginsberg; Shaoli Che; Scott E Counts; Elliott J Mufson
Journal:  NeuroRx       Date:  2006-07

2.  Nasal amyloidosis in two Quarter Horses.

Authors:  G Nappert; A Vrins; M Doré; M Morin; M Beauregard
Journal:  Can Vet J       Date:  1988-10       Impact factor: 1.008

3.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.

Authors:  X Jiang; J N Buxbaum; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Recurrent amyloid tumor of the parotid gland.

Authors:  J Vavrina; W Müller; J O Gebbers
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

5.  A DNA test for Indiana/Swiss hereditary amyloidosis (FAP II).

Authors:  M R Wallace; P M Conneally; M D Benson
Journal:  Am J Hum Genet       Date:  1988-08       Impact factor: 11.025

6.  Nucleolar organising regions in cervical intraepithelial neoplasia.

Authors:  D C Rowlands
Journal:  J Clin Pathol       Date:  1988-11       Impact factor: 3.411

7.  Freiburg Neuropathology Case Conference : Spinal Cord Compression Due to a Lesion Adjacent to the Dens Axis.

Authors:  C A Taschner; S Doostkam; U Hubbe; H E Schaefer; H Urbach; C Beck; M Prinz
Journal:  Clin Neuroradiol       Date:  2016-03       Impact factor: 3.649

8.  Use of nucleolar organiser regions (NOR's) for diagnosing gynaecological neoplasia.

Authors:  A J Wood
Journal:  J Clin Pathol       Date:  1989-07       Impact factor: 3.411

9.  Nucleolar organiser region associated proteins in cutaneous melanotic lesions: a quantitative study.

Authors:  J Crocker; N Skilbeck
Journal:  J Clin Pathol       Date:  1987-08       Impact factor: 3.411

10.  High molecular weight glycosaminoglycans in AA type amyloid fibril extracts from human liver.

Authors:  J H Magnus; S O Kolset; G Husby
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.